Effect of timing and sequence of hyperthermia and cyclophosphamide on a neurogenic rat tumor (BT4A) in vivo

Dahl, Olav; Mella, Olav

doi:10.1002/1097-0142(19830915)52:6<983::aid-cncr2820520609>3.0.co;2-w

Cited by 36 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Temperature achieved in 10% of the target volume ( • C). T 20 Temperature achieved in 20% of the target volume ( • C). T 50 Temperature achieved in 50% of the target volume ( • C).…”

Section: Definition Of Thermometric Parametersmentioning

confidence: 99%

“…Based on preclinical studies, the delivery of simultaneous CT and HT is recommended to achieve the greatest chemosensitization effect by HT [55,142]. However, in contrast to experimental results [20,55], most of the prospective studies listed in Table 9 were designed to deliver heat sequentially, and in most studies the CT drugs were administered prior to HT. Despite the fact that a considerable supra-additive or synergistic effect can be achieved by the simultaneous delivery of CT and RT, the sequential application of CT and HT may protect normal tissues from chemosensitization.…”

Section: Evidence For Predictive Values Of Thermometric Parameters In Clinical Studies Combining Ht and Ctmentioning

confidence: 99%

“…Multiple preclinical studies have been designed to unravel the relationship between biological mechanisms induced by HT and thermometric parameters as predictors of tumor response [15][16][17][18][19][20]. The parameters investigated in these studies include the temperature achieved during HT [6,15], heating duration, thermal dose [21], time interval between HT and the other treatment modality [15,22,23], the number of HT sessions [24], and the sequence of treatment modality [15,25,26].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment

Ademaj

Veltsista

Ghadjar

et al. 2022

Cancers

View full text Add to dashboard Cite

Hyperthermia (HT) is a cancer treatment modality which targets malignant tissues by heating to 40–43 °C. In addition to its direct antitumor effects, HT potently sensitizes the tumor to radiotherapy (RT) and chemotherapy (CT), thereby enabling complete eradication of some tumor entities as shown in randomized clinical trials. Despite the proven efficacy of HT in combination with classic cancer treatments, there are limited international standards for the delivery of HT in the clinical setting. Consequently, there is a large variability in reported data on thermometric parameters, including the temperature obtained from multiple reference points, heating duration, thermal dose, time interval, and sequence between HT and other treatment modalities. Evidence from some clinical trials indicates that thermal dose, which correlates with heating time and temperature achieved, could be used as a predictive marker for treatment efficacy in future studies. Similarly, other thermometric parameters when chosen optimally are associated with increased antitumor efficacy. This review summarizes the existing clinical evidence for the prognostic and predictive role of the most important thermometric parameters to guide the combined treatment of RT and CT with HT. In conclusion, we call for the standardization of thermometric parameters and stress the importance for their validation in future prospective clinical studies

show abstract

“…Temperature achieved in 10% of the target volume ( • C). T 20 Temperature achieved in 20% of the target volume ( • C). T 50 Temperature achieved in 50% of the target volume ( • C).…”

Section: Definition Of Thermometric Parametersmentioning

confidence: 99%

Section: Evidence For Predictive Values Of Thermometric Parameters In Clinical Studies Combining Ht and Ctmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment

Ademaj

Veltsista

Ghadjar

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…In contrast, most chemotherapeutic agents used clinically at present are carcinogenic in their own right. Although it is unlikely that hyperthermia by itself would be of much use in the localized control of tumour growth, hyperthermia in conjunction with simultaneously applied chemotherapy can result in a synergistic therapeutic index (Dahl and Mella 1983). It is not known, though, whether this synergism is greater in tumour than in normal tissue.…”

Section: Discussionmentioning

confidence: 98%

Hyperthermia, chemotherapeutic agents and oncogenic transformation

Hei

Hall

Kushner

et al. 1986

International Journal of Hyperthermia

View full text Add to dashboard Cite

The modulating effects of hyperthermia on cytotoxity and oncogenicity of several chemotherapeutic agents were investigated using the C3H 10T1/2 cell system. Logarithmic phase cultures of 10T1/2 cells were treated with various doses of cis-platinum or bleomycin sulphate for 2 h, either alone or with simultaneous hyperthermia (42 degrees C for 2 h). In a second set of experiments, cells were treated for 24 h with either melphalan or cis-platinum followed by a 2 h heat treatment. While hyperthermia alone was found to be ineffective in inducing oncogenic transformation and was only moderately cytotoxic, concurrent hyperthermia with drug treatment enhanced both the toxicity and oncogenic transforming potential of drugs 3-4-fold in C3H 10T1/2 cells. Sequential heat after drug treatment, however, was found to increase toxicity slightly but had no effect on the oncogenicity of the drugs.

show abstract

“…Проведенные исследования показали, что злокачественные глиомы чувствительны к цитотоксическому влиянию тепла, причем это влияние усиливается в сочетании с химиопрепаратами CCNU и BCNU. Поэтому совместное применение гипертермии и лучевой терапии для более эффективного лечения злокачественной опухоли глиобластомы является биологически обоснованным [44].…”

unclassified

Current Approaches to Chemoradiotherapy for Malignant Gliomas

et al. 2014

View full text Add to dashboard Cite

High-grade malignant gliomas (WHO grade G III–IV) account for more than 50% of all primary brain tumors. Despite aggressive treatment, survival rates are still very low with a median reported survival of no more than 1.5 years.Radiation therapy is an integral part of the combined treatment, but often does not influence lethally on resistant tumor cells. Thereby, in recent decades there has been an active search for novel approaches to the treatment of malignant gliomas (chemotherapeutic drugs, biological modifiers, local hyperthermia). Experimental data showed that the effect of high temperatures has both a direct damaging effect on tumor cells and a sensitizing effect. Significant advantages are achieved when the complex treatment of different malignant tumorsincludes local hyperthermia. However data on the treatment of patients with primary and recurrent gliomas G III–IV using local hyperthermia are scarce.The literature review is given in the article provides an overview of the existing treatment methods for brain tumors.

show abstract

Effect of timing and sequence of hyperthermia and cyclophosphamide on a neurogenic rat tumor (BT4A) in vivo

Cited by 36 publications

References 23 publications

Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment

Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment

Hyperthermia, chemotherapeutic agents and oncogenic transformation

Current Approaches to Chemoradiotherapy for Malignant Gliomas

Contact Info

Product

Resources

About